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PVIEWPOINT AND COMMENTARY Viewpoint
Screening Asymptomatic
Subjects for Subclinical Atherosclerosis
Can We, Does It Matter, and Should We?
Prediman K. Shah, MD
Los Angeles, California
Unheralded vaso-occlusive cardiovascular events (myocardial infarction, sudden death, and stroke) are common man-
ifestations of atherothrombotic vascular disease, and accurate identification of individuals at risk of such events is
highly desirable. Risk factor assessment and management have been the cornerstones of preventive strategies but
are constrained by less than desirable accuracy and less than optimal compliance, respectively. In selected popula-
tions, noninvasive imaging using carotid ultrasound and/or coronary calcium score can incrementally refine risk as-
sessment and may allow for improved adherence and better matching of preventive interventions to the magnitude
of risk. Further refinements in the future may also be possible with novel biomarkers and measures of plaque
phenotype. (J Am Coll Cardiol 2010;56:98–105) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.09.081i
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(urden of Cardiovascular Disease
ecently, I heard the famous author Dr. Deepak Chopra state
n television: “We are all on death row; the only uncertainty is
he length of reprieve and the method of execution” (1). As
hysicians, we strive to prolong life by delaying death and
mproving quality of life; any references to preventing death are
bviously illusory because the only thing certain after birth is
eath. Atherosclerotic cardiovascular disease leading to coro-
ary heart disease and stroke continue to be the leading causes
f morbidity and mortality in much of the world (2). Cardio-
ascular disease accounts for nearly one-third of all deaths
orldwide (17 million in 1999 and projected to be 25 million
n 2020). In the U.S., cardiovascular disease and stroke cause 1
eath every 33 to 37 s and cumulatively cause more annual
eaths than cancer, respiratory disease, accidents, and diabetes
ombined (2). About 16 million Americans have coronary
eart disease, and each year nearly 800,000 have a first acute
yocardial infarction, 430,000 have a recurrent myocardial
nfarction, and nearly 800,000 have a first or recurrent stroke
2). Cardiovascular disease was estimated to have cost the U.S.
ealth care system more than $400 billion in 2008. During the
ast several decades, we have witnessed significant gains
gainst cardiovascular disease, with a significant decline in
ge-adjusted mortality; however, with the aging baby boomers
nd continually rising trends in obesity and metabolic syn-
rome/diabetes, we are likely to see a reversal of these gains
ithin the coming decades with disastrous human and fiscal
rom the Atherosclerosis Research Center, Division of Cardiology and Cedars Sinai
eart Institute, Los Angeles, California.9
Manuscript received February 9, 2009; revised manuscript received September 8,
009, accepted September 22, 2009.mplications. Therefore, prevention of atherosclerotic cardiovas-
ular events (myocardial infarction, sudden death, and stroke)
emains a major imperative for health care professionals.
The process of atherosclerosis, now considered to be a
hronic immunoinflammatory disease of medium- and large-
ized arteries, often begins in childhood and adolescence and
requently remains clinically dormant until plaque rupture or
laque erosion leads to abrupt thrombosis triggering acute
linical events (3). In 2008, the sudden cardiac death of Tim
ussert, a journalistic icon, brought focus on the value and
imitations of current strategies for preventing unheralded
ardiovascular events in asymptomatic subjects. Approximately
0% to 60% of major occlusive atherosclerotic cardiovascular
vents (myocardial infarction, sudden death) occur as the first
anifestation (unheralded events), accounting for 700,000
uch events annually in the U.S. (2). The identification of
ubjects at risk of such events is obviously important, if
dentification leads to implementation of and compliance with
ffective preventive measures that reduce such risk. Stress test-
ng to detect a flow-limiting coronary stenosis among asymp-
omatic subjects is unlikely to identify a significant majority of
t-risk individuals because nearly 70% of acute coronary events
esult from coronary lesions that are not hemodynamically
ignificant or flow limiting before the event (4).
ramingham Risk Score (FRS) and
ardiovascular Events: Good but Not Good Enough
he Framingham study provided critical and extremely
aluable information regarding risk factors associated with
he development of atherosclerotic cardiovascular disease
5–7). The INTERHEART study demonstrated that nearly
0% to 95% of population-attributable risk of myocardial
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July 6, 2010:98–105 Screening for Atherosclerosisnfarction is related to 9 potentially modifiable risk factors
smoking, apoprotein B/apoprotein A1 ratio, hypertension,
iabetes, abdominal obesity, psychosocial factors, daily con-
umption of fruits and vegetables, regular alcohol intake,
nd regular physical activity) that apply to men and women,
ld and young, and in all regions of the world (8). Thus, risk
actor inventory–based prediction models using the FRS
ave been recommended as the cornerstone for risk strati-
cation of asymptomatic subjects and matching intensity of
reventive interventions (specifically, lipid-lowering drug
herapy and cholesterol targets) to the magnitude of the
redicted risk, as suggested by the National Cholesterol
ducation Program (NCEP) and the Adult Treatment
anel III (ATP III) (9,10). Assessment of a few readily
vailable clinical and laboratory variables such as age, sex,
otal cholesterol level, high-density lipoprotein cholesterol
evel, smoking status, and systolic blood pressure are used to
alculate a 10-year risk of cardiovascular events. According
o the NCEP/ATP III guidelines, subjects are considered to
e at low risk if the estimated 10-year event rate is 10%,
t high risk if the 10-year event rate is 20%, and at
ntermediate risk if the 10-year event rate is between 10%
nd 20%. Based on this scheme of risk stratification, NCEP
uidelines suggest cholesterol goals for each of the subsets
9,10). In 2003, the American College of Cardiology
ethesda Conference on Atherosclerosis Imaging suggested
hat low risk should be defined as a 10-year risk of5% and
ntermediate risk defined as a 10-year risk of 6% to 20%.
lthough FRS and NCEP/ATP III guidelines are relatively
imple, inexpensive, and useful, they are not good enough
y themselves (11). Limitations of the FRS and NCEP/
TP III guidelines include a substantial underestimation of
ifetime risk, especially in women when only a 10-year risk
odel is used, misclassification of high-risk subjects as low
r intermediate risk, and misclassification of very low-risk
ubjects into higher strata of risk (11). Karim et al. (12)
howed that in an ethnically diverse group of 498 asymp-
omatic men and women, 312 (63%) had a low FRS, and of
hese, 214 (69%) had noninvasive imaging evidence of
ubclinical atherosclerosis in 1 of the 3 vascular beds
coronary, aortic, and carotid). In the same study, of the 68
ubjects with subclinical atherosclerosis in all 3 vascular
eds, 35% had a low-risk FRS, 41% had an intermediate-
isk FRS, and only 23% had a high-risk FRS (12). Further-
ore, Akosah et al. (13) pointed out the shortcomings of
he FRS in a study of 222 patients (men younger than 55
nd women younger than 65 years of age) presenting with
heir first acute myocardial infarction over a 3-year period
ho were asymptomatic before the acute event. Based on
heir FRS, 75% of these patients would have been consid-
red ineligible for statin use under the current NCEP
uidelines that match intensity of treatment to the baseline
RS (13). A minority of patients with coronary heart
isease have none of the traditional risk factors, but, more
mportantly, in a large proportion of patients with 1 risk
actors, coronary heart disease does not develop (14). Fur- thermore, there is considerable
ariation in the severity of ath-
rosclerotic burden at any given
evel of risk factor exposure, pre-
umably attributable to addi-
ional known or unknown ge-
etic and environmental risk
actors and risk modifiers. The
RS also places a substantial
umber of women in the low-
isk category using 10-year risk
stimates even though they have
high lifetime risk; thus, very few
omen will reach the threshold for
nitiation of lipid-lowering or as-
irin therapy (11,15). The FRS
oes not incorporate family his-
ory and many of the components
f metabolic syndrome, both of which are important risk
actors for coronary heart disease. A substantial number
60% to 70%) of unheralded cardiovascular events occur in
low” and “intermediate” risk categories (16). Nasir et al. (17)
howed that 79% of young men and women with significant
oronary atherosclerotic burden displayed by coronary calcifi-
ation were not eligible for pharmacotherapy based on current
CEP-ATP III guidelines. Although groups of patients can
e placed in risk categories, many patients at risk would not be
ecommended for lipid-modifying therapy, and many patients
n whom an event will not develop would be needlessly
argeted for aggressive medical management (11). Thus, FRS
nd NCEP/ATP III guidelines, although reasonable for pop-
lations, remain suboptimal for individual subjects. In 2007,
idker et al. (18) introduced the Reynolds Risk Score (RRS)
or risk assessment in women, which, in addition to traditional
isk factors, also incorporated high-sensitivity C-reactive pro-
ein (hsCRP) and family history of premature coronary artery
isease. The RRS reclassified 30% of women estimated to be in
he intermediate-risk group by the traditional FRS into a
igher or lower risk category with improved accuracy. Subse-
uently, the RRS was tested in 10,724 initially healthy non-
iabetic men age 50 years or older from the Physicians Heath
tudy who were followed for 10.8 years (19). The RRS was
hown to be superior to the traditional FRS in predicting risk.
espite improved risk assessment with RRS compared with
he traditional FRS, neither scheme is sufficiently accurate for
ndividual risk assessment and, unlike the FRS, the RRS has
ot yet been fully validated outside the Women’s Health Study
nd Physicians Health Study participants.
nconditional Treatment of All:
hy Bother Screening for Risk?
hy Not Treat Everyone?
idespread application of preventive interventions (lifestyle,
edications) without previous risk stratification (i.e., uncondi-
Abbreviations
and Acronyms
CCS  coronary calcium
score
CIMT  carotid artery
intima-media thickness
CT  computed
tomography
FRS  Framingham risk
score
hsCRP  high-sensitivity
C-reactive protein
NCEP  National
Cholesterol Education
Program
RRS  Reynolds Risk
Scoreional interventions for all) would be most appropriate if
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Screening for Atherosclerosis July 6, 2010:98–105nterventions were safe, inexpensive, easily implemented,
ighly effective, and associated with high compliance and low
iscontinuation rate. Unfortunately, in the real world, there is
o such thing as universally effective, safe, and inexpensive
revention that carries a high degree of compliance. Lifestyle
odification, although clearly important and effective, is dif-
cult to implement on a wide scale because of social, cultural,
nd economic factors; drug therapy, specifically lipid-
odifying therapy, although effective is limited by cost, need
or lifelong use, intolerance because of nuisance type, and less
ommonly, more serious side effects, and overall resistance of
any subjects to lifelong use, thereby limiting long-term
ompliance. Furthermore, drug therapy, specifically statin ther-
py, only addresses about 30% to 50% of the risk, leaving a
onsiderable amount of residual risk.
Therefore, we must continue to search for better ways of
dentifying at-risk individuals so that aggressive preventive
easures can be targeted to this population while sparing those
ho are at no or extremely low risk the cost and side effects of
rotracted and potentially lifelong drug therapy. Unfortu-
ately, FRS only partially fulfills the need, and the currently
vailable biomarkers, specifically hsCRP and lipoprotein-
ssociated phospholipase A2, provide statistically significant
ut clinically modest incremental prognostic value and thus are
ot sufficiently precise to markedly improve the discriminant
alue of FRS. Because we are primarily talking about athero-
hrombotic cardiovascular disease, it is logical to ask the
uestion: instead of simply measuring risk factors that at best
ave only a modest relationship to the presence and extent of
therosclerosis and cardiovascular events (high sensitivity but
ow specificity), can we actually detect the disease itself (i.e.,
therosclerosis) before it causes catastrophic events? After all,
etection of subclinical atherosclerosis identifies the biological
ubstrate for all but the rarest forms of ischemic cardiovascular
isease, and detecting subclinical atherosclerosis provides an
ntegrated view of cumulative exposure to known and un-
nown risk factors and risk modifiers.
an We Detect Subclinical Atherosclerosis
oninvasively, and Does It Matter?
here are multiple noninvasive imaging techniques that can
dentify subclinical atherosclerosis in various vascular beds,
tandard Risk Factor-Adjusted Coronary Eventates in 4 Racial/Ethnic Groups of Asymptomaticubjects Ba ed on Coronary Calcium ScoreMulti-Ethn c Study of Athe sclerosis)
Table 1
Standard Risk Factor-Adjusted Coronary Event
Rates in 4 Racial/Ethnic Groups of Asymptomatic
Subjects Based on Coronary Calcium Score
(Multi-Ethnic Study of Atherosclerosis)
Calcium Score Hazard Ratio
Annual Number and Rate
of Coronary Events
0 (n  3,409) 1 15 (0.10%)
1–100 (n  1,728) 3.6 39 (0.59%)
101–300 (n  752) 7.73 41 (1.43%)
300 (n  833) 9.67 67 (2.87%)
ote that 90% of all events occurred in subjects with coronary calcification, and nearly 50% of the
ubjects had no coronary calcification. Adapted from Detrano et al. (24).ncluding ultrasonography, coronary Ca2 assessment by
Pomputed tomography (CT), noninvasive CT angiography,
nd magnetic resonance imaging. Although all of these
ethods have their relative advantages and drawbacks,
maging of coronary arteries to identify coronary calcium, a
alidated measure of atherosclerotic plaque, by computed
omography without contrast and use of B-mode ultra-
onography to detect carotid intima-media thickness and
arotid plaque have been most extensively studied and have
he potential to be suitable screening tools for the detection
f subclinical atherosclerosis.
oronary calcium score (CCS). Coronary calcium detec-
ion by CT has been shown to identify atherosclerotic
laque and to quantitatively assess coronary calcium; using
he Agatston CCS, a surrogate for plaque burden, has been
hown to provide powerful prognostic information in mul-
iple studies involving both sexes and multiple ethnic groups
20–35). Furthermore, CCS has been shown to provide
rognostic information that is independent of and substan-
ially incremental to that provided by the FRS and hsCRP
20–35) (Table 1). The CCS can provide individual risk
ssessment and can reclassify the low and particularly
ntermediate Framingham risk cohort into lower- and
igher-risk strata, as shown by Preis et al. (36) in a study
nvolving 3,529 asymptomatic subjects from the Framing-
am Offspring Cohort (Table 2). Absence of coronary
alcium (CCS  0), while not excluding the presence of
oncalcified plaque, virtually excludes significant coronary
therosclerosis, but more importantly is associated, in an
symptomatic population, with an extremely low risk of
ardiovascular events in the ensuing 5 to 10 years ranging
rom annual event rates of 0% to 0.6% (32). The higher
vent rates reported in subjects with a 0 coronary calcium
core by Greenland et al. (25) came from a study that used
-mm thick slices, which is known to result in data loss
ompared with 3-mm slices. In an observational cohort of
5,765 asymptomatic subjects from published studies,
6,106 (45%) had zero coronary calcium; their annual event
ate was only 0.027% (32). Blaha et al. (37) reported from an
symptomatic cohort of 44,052 subjects referred for coro-
ary calcium scanning that 19,898 of these subjects (45% of
he total cohort) had a CCS of 0 and a 10-year all-cause
eclassification of Framingham Risk by Coronaryalcium Score in the Framingham Offspring andhird-Generation Cohort
Table 2
Reclassific tio of Framingham Risk by Coronary
Calcium Score in the Framingham Offspring and
Third-Generation Cohort
FRS
FRS  Coronary Calcium Score
Low Intermediate High
Low (n  2,410) 89% (92%) 11% (8%) 22% (39%)
Intermediate (n  595) 25% (25%) 53% (35%)
High (n  245) 100% (100%)
oronary calcium score criterion was either the 90th percentile value or absolute score 100;
ata using the absolute coronary calcium score is shown in parentheses. Note that in the FRS
ntermediate group, coronary calcium score reclassified 25% of subjects into a lower risk stratum
nd 22% to 39% into a higher risk stratum. Eight percent to 11% of those at low risk FRS level were
pgraded to intermediate risk level with the addition of coronary calcium score. Data adapted from
reis et al. (36).
FRS  Framingham risk score.
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July 6, 2010:98–105 Screening for Atherosclerosisortality rate of 1%; the mortality rate was 2-fold higher in
ubjects with minimal coronary calcification with a CCS of
to 10 and nearly 9-fold higher with a CCS 10 (37). In
systematic review of 13 published studies involving 64,873
symptomatic subjects undergoing coronary calcium assess-
ent and prognostic evaluation, 25,903 subjects (45% of
ohort) with zero coronary calcium were identified whose
ardiovascular event rate was 0.56% during a 4.25-year
ollow-up (38). In another registry study involving 25,000
ubjects, Budoff et al. (23), in a follow-up extending up to
2 years, demonstrated a mortality rate of 0.4%. These
bservations highlight the fact that asymptomatic subjects
ith a CCS of 0 have an extremely low 5- to 10-year risk of
ardiovascular and all-cause mortality and that such patients
re unlikely to benefit from lipid-lowering therapy and any
dditional downstream tests for vaso-occlusive disease. In-
erestingly, in a cohort of 900 subjects with diabetes, a CCS
f 0 was associated with a 5-year survival rate of 98.8%, and
he survival of diabetic and nondiabetic patients with a CCS
f 0 was remarkably similar (98.8% vs. 99.4%) (30). In
nother prospective study of patients with type 2 diabetes, a
CS 10 was associated with a zero event rate at 2 years of
ollow-up (39). Such very low-risk individuals constitute
0% to 50% of asymptomatic cohorts (23), are unlikely to
enefit from aggressive preventive interventions, and may be
ecommended only to follow a healthy lifestyle and could
ell be spared the cost and side effects of aggressive
ipid-lowering therapy. It is, however, important to point
ut that in a symptomatic population with clinical evidence
f myocardial ischemia, absence of coronary calcium is not
otally reassuring and may be associated with a higher event
ate (annual event rate of 3.6%) (40–42). This is consistent
ith recent observations from noninvasive contrast CT
oronary angiography revealing that 6% to 11.6% of subjects
ay have only noncalcified plaque, which would be missed
n coronary calcium scoring (43,44). The major drawbacks
f this CT-based technique include exposure to a small
mount of radiation, which may be particularly undesirable
n young subjects, especially women, and the very rare but
efinite instance in which a subject with only a noncalcified
laque is labeled as normal (43,44); such an eventuality is
uite rare in asymptomatic subjects. When a coronary event
ccurs in a subject with a CCS of 0, besides a noncalcified
ulprit plaque, one must also consider other unpredictable
easons for cardiovascular events that have nothing to do
ith atherosclerosis such as acute myocarditis simulating
yocardial infarction, coronary embolism, coronary dissec-
ion presenting as an acute coronary syndrome, and stress-
nduced acute myocardial syndrome in women. None of
hese relatively uncommon nonatherosclerotic events could
e predicted by any known tests.
-mode ultrasonography. B-mode ultrasound imaging of
arotid arteries provides yet another noninvasive, simple, and
elatively inexpensive modality for the detection of subclinical
therosclerosis or pre-atherosclerosis as measured by a thick-
ned intima-media (carotid artery intima-media thickness cCIMT]); this technique is safe and, unlike coronary calcium
canning, carries no risk of radiation exposure (45,46). Several
rospective studies, including the MESA (Multi-Ethnic Study
f Atherosclerosis), of asymptomatic subjects demonstrated
hat increased CIMT over 75th percentile for a person’s age,
ex, and race (using nomograms from large population-based
tudies) is associated with future risk of myocardial infarction,
troke, and death from coronary heart disease that in most
tudies was independent of traditional risk factors (45,46).
urthermore, several large studies have shown that the pres-
nce of carotid plaque on ultrasonography (defined as focal
hickening of the carotid wall that is at least 50% greater than
hat of surrounding wall or as a focal region with CIMT1.5
m that is distinct from adjacent boundary and protrudes into
he lumen) in asymptomatic subjects is associated with in-
reased risk of cardiovascular events that is comparable to or
etter than that of increased CIMT (46). A recent meta-
nalysis by Lorenz et al. (47) reported significant relative risks
f coronary heart disease of 1.26 for myocardial infarction and
.32 for stroke for each 1-SD increment of CIMT.
omparative prognostic value of coronary calcium scanning
ersus carotid ultrasonography. Although atherosclerosis is
enerally considered to be a diffuse or at least multifocal process
nd both carotid ultrasonography as well as coronary calcium
canning can detect subclinical atherosclerosis, CIMT and
CS are only modestly correlated in individual subjects, with
ome patients exhibiting a CCS of 0 in the context of abnormal
IMT or carotid plaque and some patients with an abnormal
CS exhibiting normal CIMT and no carotid plaque. Two
ecent prospective studies compared the incremental prognos-
ic value of CIMT and coronary calcium scanning in initially
symptomatic subjects (48,49). Newman et al. (48) found that
n adults older than 70 years, CIMT and CCS similarly
redicted cardiovascular disease and coronary heart disease, but
IMT was a better predictor of stroke. However, Folsom et al.
49) reported the results of MESA and showed that the CCS
as a stronger predictor of cardiovascular events than CIMT.
or cardiovascular events, the traditional risk factor-adjusted
azard increased 2.1-fold for each SD greater level of log-
ransformed CCS versus 1.3-fold for each SD greater maxi-
um CIMT; comparable differences in relative risk were noted
or coronary heart disease (49). That CIMT was modestly
etter than CCS in predicting stroke reflects a closer correla-
ion between stroke and the relevant vascular territory. These
esults were further supported by receiver-operator character-
stic analysis in which adding CCS to risk factor analysis
ignificantly improved the area under the curve, whereas
IMT provided little additional value (49).
maging of Subclinical Atherosclerosis:
e Can and It Matters, but Should We?
t is abundantly clear that subclinical atherosclerosis in 2
ajor consequential vascular beds (coronary and carotid)
an be detected by noninvasive imaging and such assessment
an clearly refine Framingham risk assessment in individual
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Screening for Atherosclerosis July 6, 2010:98–105atients and do it better than biomarkers such as hsCRP
nd lipoprotein-associated phospholipase A2. Large-scale
creening for subclinical atherosclerosis would be useful if it
s simple, easily available, relatively safe and effective, adds
alue to prediction leading to better selection of subjects for
ggressive treatment and sparing very low-risk subjects
nlikely to benefit, and improves compliance and adherence
o risk-modifying interventions. The CCS and CIMT fulfill
any but not all of these requirements; in particular, the
dded value of imaging-guided management in improving
atient outcomes has not yet been proven using random-
zed, controlled clinical trials, and therefore, in that sense, to
purist the “jury” is still out. However, we must acknowl-
dge that FRS-based management using NCEP guidelines
as also not been subjected to similar rigorous clinical trials
nd yet is accepted as a reasonable strategy for risk detection
nd modification based on purely observational data. Hold-
ng noninvasive imaging to a different standard even when
ts prognostic value has been unequivocally demonstrated to
e significantly incremental to FRS, especially among low-
nd intermediate-risk categories, is indicative of a double
tandard (50). Despite the lack of randomized clinical trial
vidence, the totality of observational evidence supports
maging-guided management because: 1) detecting disease
he consequences of which we are trying to prevent is likely
etter than simply identifying risk factors that have only
modest specificity and a highly variable relationship to
he development of disease; 2) imaging can reclassify
ntermediate- and low-risk FRS subjects into higher-risk
trata for which more aggressive medical therapy and
ower cholesterol targets would be recommended, thereby
angibly altering therapy while at the same time identi-
ying a very low-risk cohort that could avoid aggressive
rug therapy because of a lack of likely near-term benefit;
nd 3) imaging-based identification of at-risk subjects may
mprove compliance and adherence to risk-modifying inter-
entions; this is particularly germane because long-term
ompliance with effective preventive therapy results in better
utcomes, making adherence a surrogate for outcomes. A
andom-effects meta-analysis of 5 recent trials involving
2,319 patients showed that adherence to statin therapy
veraged only 65% (51). In a study involving 505 subjects on
tatin therapy followed for 3 years, Kalia et al. (51) showed
hat the overall statin compliance was lowest (44%) among
hose with a CCS in the first quartile (0 to 30), whereas 91%
f individuals with a baseline CCS in the fourth quartile
dhered to statin therapy. Multivariable analysis, after ad-
usting for cardiovascular risk factors, age, and sex, showed
hat a higher baseline CCS score was strongly associated
ith adherence to statin therapy (51). Taylor et al. (52)
ecently reported on the association of the CCS detected on
screening examination with subsequent use of statins and
spirin in 1,640 asymptomatic men 40 to 50 years of age. In
his prospective cohort followed for up to 6 years, the
resence of coronary calcification was associated with a
-fold greater likelihood of statin and aspirin use that was cndependent of NCEP risk variables and baseline medica-
ion use. These findings from a community-based nonre-
erred study population provide strong evidence of a signif-
cant and incremental impact of subclinical atherosclerosis
etection, over and above FRS-NCEP risk assessment, on
atient management, thus supporting the use of such an
pproach to refine cardiovascular risk assessment (52). It
hould be noted that an earlier small randomized trial from
he same group reported no effect of coronary calcium
etection on improvement in FRS; however, this study was
imited by the small number of subjects with coronary
alcification (only 66 of 450 subjects) and the overall very
ow-risk nature of the cohort that had a predicted a mean
0-year Framingham risk of only 5.8% (53). Favorable
esults were also reported by Orakzai et al. (54) from a study
f 980 individuals who were followed for a mean of 3  2
ears after an initial coronary calcium scan in which multi-
ariate analysis showed that a greater baseline CCS was
trongly associated with initiation of aspirin therapy, dietary
hanges, and increased exercise. Wong et al. (55) showed
hat potentially important risk-reducing behaviors are rein-
orced by the knowledge of a positive coronary calcium scan
ndependent of pre-existing coronary risk factors. In another
mall study, motivation for smoking cessation and cessation
ates were higher in cigarette smokers shown to have carotid
laque compared with those without plaque (56).
Therefore, the recommendations of the SHAPE (Screen-
ng for Heart Attack Prevention and Education) Task
orce, although based on a wealth of published observa-
ional data but not randomized, controlled trials, represent a
easonable blueprint for an imaging-augmented strategy for
isk assessment and management (57). The SHAPE Task
orce recommended noninvasive atherosclerosis imaging of
ll asymptomatic men (age 45 to 75 years) and women (age
5 to 75 years), except those at very low risk, to augment
onventional cardiovascular risk assessment algorithms (57).
ecent observations from 2,611 participants 30 to 65 years
f age from the Dallas Heart Study provided evidence in
avor of the SHAPE algorithm because SHAPE recom-
endations resulted in bidirectional reclassification of eli-
ibility for lipid-lowering therapy in the participants (58).
pplication of imaging according to the SHAPE guidelines
o the Dallas Heart Study Cohort reclassified 35% to 48% of
he cohort into a higher-risk stratum, making them eligible
or lipid-lowering therapy, and the number needed to reclassify
individual as newly eligible (or no longer eligible) for
ipid-lowering therapy ranged from 4.1 to 7.8, depending on
he coronary calcium score threshold used (58).
An important consideration in any recommendation for
arge-scale screening is the cost-effectiveness of such an
pproach. Diamond and Kaul (59) recently compared the
osts and effectiveness of unconditional treatment of all risk
actor–based treatment recommended by the NCEP and
maging-based treatment recommended by the SHAPE
ask Force while making certain assumptions regardingosts of imaging and treatment with statins. The Diamond
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July 6, 2010:98–105 Screening for Atherosclerosisnd Kaul (59) analysis supported cost-effectiveness of the
HAPE algorithm over the NCEP strategy, as also found
y the SHAPE Task Force analysis (57), but suggested that
nconditional treatment was most cost-effective. However,
iamond and Kaul (59) were quick to point out that if the
HAPE algorithm improves adherence to preventive ther-
py, its cost-effectiveness could surpass unconditional treat-
ent. Similarly, Hecht (50) pointed out that reducing
maging costs to $100, instead of the $400 assumed by
iamond and Kaul (59), would make imaging-based treat-
ent the most cost-effective option. Although potential
isks associated with radiation exposure are of concern, the
ctual radiation exposure with coronary calcium scanning is
mall (0.6 to 1.0 mSv for electron-beam CT and 0.9 to 2.0
Sv for multidetector CT), although it can vary by 10-fold
epending on many technical factors; these can be opti-
ized and standardized to reduce the actual amount of
adiation exposure. A recent analysis suggested that there
ould be a small increase in lifetime risk of cancer with the
adiation exposure entailed in a coronary CT examination
elivering a median radiation exposure of 2.3 mSv; however,
he authors acknowledge that depending on the methodol-
gy used to predict risk, the estimated cancer risk could be
igher or lower by a factor of 2 (60). Thus, there is
onsiderable uncertainty about the true magnitude of cancer
isk posed by coronary calcium scanning, especially when
he very young are excluded.
We must also be clear that although detecting subclinical
therosclerosis is a logical first step after Framingham risk
ssessment to improve prognostic value, the answer to the
uestion “plaque present or absent?” cannot be the final
olution because the amount/extent of plaque (plaque bur-
en) and the composition of plaque are likely to contribute
dditional important prognostic information and can fur-
her improve the sensitivity and specificity of noninvasive
maging for risk prediction. Adding some measures beyond
rterial structure, specifically addressing arterial function
arterial compliance and vasodilator function) (61), plaque
henotype as an index of vulnerability to acute thrombotic
vents will likely further improve imaging-based risk pre-
iction. Such approaches might include assessing plaque
omposition/configuration (inflammation, lipid core, thin
ap, increased plaque neovascularity, outward remodeling,
ntraplaque hemorrhage), circulating biomarker reflective of
iological processes relevant to plaque rupture (proteomics/
etabolomics/circulating biomarkers), and genotypes that
re predictive of risk. Such a comprehensive multimodality
pproach is currently under way in the High Risk Plaque
nitiative, which is likely to provide valuable new informa-
ion in the near future (62).
onclusions
lthough randomized, controlled prospective data to prove
he efficacy of imaging-guided risk assessment in improving
linical outcomes are not available and such studies shoulde encouraged, the large amount of observational cohort and
rospective longitudinal data support selective use of
maging-based risk assessment, especially in intermediate-
isk groups identified by the FRS (Fig. 1) (63). Therefore,
he answer to the question (screening asymptomatic subjects
or subclinical atherosclerosis: can we, does it matter, and
hould we?) is yes, we can, it matters, and we should in
elected subjects because: 1) a large body of published
vidence supports incremental value of noninvasive
maging-guided risk assessment over and above that of FRS,
specially among intermediate- and possibly low-risk co-
orts; 2) imaging-based bidirectional reclassification of
atients into different strata of risk has tangible clinical value
nd implications for better matching of intensity of preven-
ion to expected risk; and 3) despite earlier reports, new
vidence is accumulating that imaging may improve adher-
nce to and compliance with risk-modifying interventions.
lthough data support the superior relative prognostic value
f coronary calcium scanning relative to carotid ultrasonog-
aphy as a preferred screening strategy, a reasonable alter-
ative strategy for imaging might involve first using carotid
ltrasonography (since it is safe and radiation free), and if
arotid plaque or markedly thickened CIMT is discov-
red, no further screening is needed; however, if carotid
ltrasonography is normal, a coronary calcium scan might
e reasonable because some patients with normal findings
n carotid ultrasonography may actually have coronary
therosclerosis.
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